Drug Shortages for Prescription Amphetamine Derivatives
Authors:
- 1 April 2025
- journal article
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 30 (2) , 206-211
Abstract
OBJECTIVE: Amphetamine derivatives are first-line medications for attention-deficit/hyperactivity disorder (ADHD). Recently, there have been increasing reports of drug shortages involving amphetamine derivatives. The objective of this study is to describe trends in drug shortages impacting prescription amphetamine derivatives. METHODS: Drug shortage data were retrieved from the University of Utah Drug Information Service (UUDIS) from January 2001 to December 2023. Using UUDIS data, we analyzed all reported shortages of amphetamine derivatives, including amphetamine salts, dexmethylphenidate, dextroamphetamine, lisdexamfetamine, and methylphenidate. Specific dosage forms, including extended-release and immediate-release oral preparations and transdermal patch formulations were examined. Data were analyzed focusing on shortage trends over time, specific amphetamine product involved, product formulation, reason for shortage, shortage duration (for resolved shortages), and single source status (made by 1 manufacturer/facility). RESULTS: There were a total of 26 shortages impacting amphetamine derivatives verified by UUDIS from January 1, 2001 to December 31, 2023. The years with the greatest number of amphetamine shortages were 2012, 2013, 2015, and 2023, each with 7 total shortages. The mean shortage duration for resolved shortages was 20.7 months, with a range of 1.3 months to 61.6 months. The longest shortage (61.6 months) was for methylphenidate extended-release tablets. The majority of manufacturers (58%) did not disclose a reason for shortage. CONCLUSIONS: Shortages for amphetamine derivatives have increased recently, limiting access to first-line therapy for ADHD. Inaccessibility of these agents can have negative implications for the cognitive development and functioning of children and adolescents, leading to comorbid mental health disorders.Keywords
This publication has 12 references indexed in Scilit:
- Pediatric ADHD Medication Errors Reported to United States Poison Centers, 2000 to 2021Pediatrics, 2023
- Risks Associated With Undiagnosed ADHD and/or Autism: A Mixed-Method Systematic ReviewJournal of Attention Disorders, 2023
- The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regionsEuropean Neuropsychopharmacology, 2023
- Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021MMWR. Morbidity and Mortality Weekly Report, 2023
- Evidence-based pharmacological treatment options for ADHD in children and adolescentsPharmacology & Therapeutics, 2022
- Top problems of adolescents and young adults with ADHD during the COVID-19 pandemicJournal of Psychiatric Research, 2021
- Attention-Deficit/Hyperactivity Disorder and Psychotropic Polypharmacy Prescribing TrendsPediatrics, 2020
- Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitionersTranslational Pediatrics, 2018
- Effect of Treatment Modality on Long-Term Outcomes in Attention-Deficit/Hyperactivity Disorder: A Systematic ReviewPLOS ONE, 2015
- Diagnostic and Statistical Manual of Mental Disorders2013